ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) HKSE
3.11
-0.07(-2.20%)
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Sector
Healthcare
Industry
Biotechnology
Employees
156
First IPO Date
September 05, 2023
Key Executives
| Name | Title | Pay | Year Born |
| Wenzhi Tian | Founder, Chief Executive Officer, Chief Scientific Officer & Chairman of the Board | 4.49M | 1965 |
| Mei Guan | Joint Company Secretary, Vice President of the Financing & Investment Strategy Department and Executive Director | 1.2M | 1983 |
| Song Li | Vice President of Research & Development and Executive Director | 1.52M | 1986 |
| Ruliang Zhang | Deputy GM, Senior Vice President & Executive Director | 1.89M | 1985 |
| Xiaodong Gan | Counsel | 0 | 1964 |
| Zhuli Wu | Chief Medical Officer | 0 | 1984 |
| Weihai He | Chief Business Officer | 0 | 1973 |
| Zikai Xiong | Senior Vice President | 0 | 1981 |
| Kin Wai Li | Joint Company Secretary | 0 | 1989 |
Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, focuses on the development of immuno-oncology therapies. Its lead product candidate is IMM01, a clinical-stage CD47-targeted molecule for the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). It also develops IMM0306, a CD47×CD20 bispecific molecule for the treatment of R/R B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, a CD47×HER2 bispecific molecule for the treatment of HER2-positive and HER2-low expressing solid tumors; IMM2520, a CD47×PD-L1 bispecific molecule for the treatment of solid tumors; IMM47, a humanized monoclonal antibody targeting CD24 for cancer treatment; MM4701, a bispecific molecule that simultaneously targets CD47 and CD24; IMM2510, a bispecific molecule with a mAb-Trap structure targeting VEGF and PD-L1; IMM27M, a CTLA-4 antibody with enhanced ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody with enhanced ADCC activity. The company was founded in 2015 and is headquartered in Shanghai, China.
